
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd has demonstrated a significant positive outlook with its proprietary PLEX technology, which enables targeted drug delivery and has shown promising results in the Phase 3 SHIELDI clinical study for its flagship product, D-PLEX100, aimed at preventing surgical site infections. The company experienced lower-than-expected net loss per share, attributed to an increase in share count due to warrant exercises, suggesting strong investor confidence and participation. Additionally, the impending pre-NDA meeting, expected to yield positive outcomes, coupled with the strategic collaboration with AdvanzPharma in the EU, underscores PolyPid's potential for successful product approval and market entry.
Bears say
PolyPid Ltd faces a negative outlook primarily due to the potential for its clinical agents to fail in delivering statistically significant results, which would significantly diminish the value of its product candidates. Additionally, even if the products demonstrate clinical success, there exists a risk of non-approval by regulatory agencies, further jeopardizing the company's value. Compounding these challenges, the complicated patent procedures raise concerns about potential revenue erosion beginning in 2036, contributing to the overall pessimistic financial outlook for the company.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares